Literature DB >> 11187966

Transgenic animals in cardiovascular disease research.

M Bader1, H Bohnemeier, F S Zollmann, O E Lockley-Jones, D Ganten.   

Abstract

Worldwide, the highest morbidity and mortality results from such cardiovascular diseases as hypertension, myocardial infarction, cardiac and renal failure, as well as stroke. Since the cardiovascular system and its regulation is quite complex, study of these disorders has been grossly limited to whole organism models. As a result, in recent years, transgenic technology has played a significant role in the discovery of specific gene products for cardiovascular regulation and disease aetiology. Genetic manipulation in rats and mice has altered the expression of numerous genes. In this review, some of the important new genetically modified animals (i.e. transgenic models) with alterations in hormone and second messenger systems involved in cardiovascular regulation are summarized.

Entities:  

Mesh:

Year:  2000        PMID: 11187966

Source DB:  PubMed          Journal:  Exp Physiol        ISSN: 0958-0670            Impact factor:   2.969


  3 in total

1.  Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat.

Authors:  Catherine J Leader; Darren J Kelly; Ivan A Sammut; Gerard T Wilkins; Robert J Walker
Journal:  Physiol Rep       Date:  2020-05

2.  Myocardial global longitudinal strain: An early indicator of cardiac interstitial fibrosis modified by spironolactone, in a unique hypertensive rat model.

Authors:  Catherine J Leader; Mohammed Moharram; Sean Coffey; Ivan A Sammut; Gerard W Wilkins; Robert J Walker
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240

Review 3.  ACE2 in Brain Physiology and Pathophysiology: Evidence from Transgenic Animal Models.

Authors:  Natalia Alenina; Michael Bader
Journal:  Neurochem Res       Date:  2018-11-15       Impact factor: 3.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.